Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?
2026-07-22 20:33
•Brendan Coffey •The Motley Fool
•• •••••• Axe Capital view
Choosing Between Vanguard Health Care and iShares Pharmaceuticals ETFs
A comparison of broad healthcare versus focused pharmaceutical exposure for 2026 portfolios.
When looking at healthcare through a South African lens, it pays to think about where you want your exposure. Vanguard Health Care ETF (VHT) casts a wide net with over 400 holdings, spreading risk but delivering modest returns. Meanwhile, iShares Pharmaceuticals ETF (IHE) narrows the focus to about 56 large pharma players, including heavyweights like Johnson & Johnson and Eli Lilly. This narrower scope brought IHE stronger returns and less volatile drawdowns over five years. Locally, there’s limited direct access to these sectors on the JSE, so currency moves like USD/ZAR matter. A rising rand erodes offshore gains, so timing currency exposure is key. If you want simplicity and cost-efficiency, VHT’s low fees are attractive. But if you’re after punchier growth with some concentration risk, IHE edges ahead. The risk? Pharma regulations or trial failures could hit IHE hard, and a weaker USD might dampen rand returns. this is just my opinion and not financial advice
I would lean towards adding IHE for South African investors who can tolerate more sector concentration and currency swings, while keeping a wary eye on USD/ZAR. VHT suits those wanting broad, steadier exposure without chasing outsized returns.
- IHE
- VHT
- USD/ZAR
- pharmaceutical regulation setbacks
- rand appreciation reducing offshore gains
6/10
The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Brendan Coffey
Categories: Healthcare, Equities
Tickers: VHT, IHE, LLY, JNJ, ABBV, MRK
Sentiment: Positive - Praised for low expense ratio (0.09%) and broad diversification with 411 holdings across the healthcare ecosystem, but criticized for underperformance relative to IHE over recent years (5.4% vs 11.8% over 5 years). Recommended for cost-conscious, diversification-focused investors. Recommended as the better buy for 2026 due to superior 5-year returns (11.8%), better year-to-date performance (17.5% vs 4.7%), and lower maximum drawdown. Higher concentration risk with 56 holdings is offset by stronger recent performance metrics.
Keywords: healthcare ETF, pharmaceutical stocks, expense ratio, portfolio diversification, ETF comparison, sector exposure
Insights:
- VHT: Neutral: Praised for low expense ratio (0.09%) and broad diversification with 411 holdings across the healthcare ecosystem, but criticized for underperformance relative to IHE over recent years (5.4% vs 11.8% over 5 years). Recommended for cost-conscious, diversification-focused investors.
- IHE: Positive: Recommended as the better buy for 2026 due to superior 5-year returns (11.8%), better year-to-date performance (17.5% vs 4.7%), and lower maximum drawdown. Higher concentration risk with 56 holdings is offset by stronger recent performance metrics.
- LLY: Positive: Major holding in both ETFs (14.2% in VHT, 22.3% in IHE), indicating strong presence in pharmaceutical sector exposure.